相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Audrey Laroche-Clary et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Reviving the guardian of the genome: Small molecule activators of p53
Daniel Nguyen et al.
PHARMACOLOGY & THERAPEUTICS (2017)
MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
Audrey Laroche et al.
ONCOTARGET (2017)
Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System
Stephen T. Hallett et al.
CELL REPORTS (2017)
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges
Shaomeng Wang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
Hui Qin Wang et al.
ELIFE (2017)
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
Kate Lynn J. Bill et al.
CLINICAL CANCER RESEARCH (2016)
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Maite Verreault et al.
CLINICAL CANCER RESEARCH (2016)
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
A-S Tigan et al.
ONCOGENE (2016)
Fortifying p53-beyond Mdm2 inhibitors
Anusha Sriraman et al.
AGING-US (2016)
Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE
Casimiro Gerarduzzi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53
Magdalena Wienken et al.
MOLECULAR CELL (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
Anusha Sriraman et al.
ONCOTARGET (2016)
Clinical Overview of MDM2/X-Targeted Therapies
Andrew Burgess et al.
FRONTIERS IN ONCOLOGY (2016)
RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas
Antonia Obrador-Hevia et al.
CANCER INVESTIGATION (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
HTSeq-a Python framework to work with high-throughput sequencing data
Simon Anders et al.
BIOINFORMATICS (2015)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
Yujun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo Kian Hoe et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
Anne Y. Saiki et al.
ONCOTARGET (2014)
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
Jorge Franco et al.
ONCOTARGET (2014)
Unravelling mechanisms of p53-mediated tumour suppression
Kathryn T. Bieging et al.
NATURE REVIEWS CANCER (2014)
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Hege O. Ohnstad et al.
CANCER (2013)
ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice
Mathew C. Casimiro et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Isabelle Ray-Coquard et al.
LANCET ONCOLOGY (2012)
Fast gapped-read alignment with Bowtie 2
Ben Langmead et al.
NATURE METHODS (2012)
Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen
Frederic Bienvenu et al.
NATURE (2010)
Variability of origin for the neocentromeric sequences in analphoid supernumerary marker chromosomes of well-differentiated liposarcomas
Antoine Italiano et al.
CANCER LETTERS (2009)
Nutlin-3 Affects Expression and Function of Retinoblastoma Protein ROLE OF RETINOBLASTOMA PROTEIN IN CELLULAR RESPONSE TO NUTLIN-3
Wei Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line
Fredrik Persson et al.
CANCER LETTERS (2008)
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Christoph R. Muller et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Identification of novel functional TBP-binding sites and general factor repertoires
Sergey Denissov et al.
EMBO JOURNAL (2007)
Amplification of CDK4 and MDM2 in malignant melanoma
V Muthusamy et al.
GENES CHROMOSOMES & CANCER (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2
TG Hofmann et al.
NATURE CELL BIOLOGY (2002)
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis
G D'Orazi et al.
NATURE CELL BIOLOGY (2002)
Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases
NA Barlev et al.
MOLECULAR CELL (2001)
Reconstitution of cyclin D1-associated kinase activity drives terminally differentiated cells into the cell cycle
L Latella et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
分享论文
